Mark S Newman

US Patent:

7462354, Dec 9, 2008

Filed:

Jun 27, 2001

Appl. No.:

09/894018

Inventors:

Alessandro Sette - La Jolla CA, US
Robert Chesnut - Cardiff-by-the-Sea CA, US
Brian D. Livingston - San Diego CA, US
Denise Marie Baker - San Diego CA, US
Mark J. Newman - Carlsbad CA, US

Assignee:

Pharmexa Inc. - San Diego CA

International Classification:

A61K 39/00
C07K 14/00
G06F 19/00

US Classification:

4241841, 4241851, 4241921, 702 19, 702 20, 530350

Abstract:

The invention relates to the field of biology. In particular, the invention relates to a method and system for designing optimized multi-epitope vaccines having selected combinations of amino acid insertions at the junctions of the multi-epitope constructs so as to minimize the number of junctional epitopes and provide vaccines with increased immunogenicity.

US Patent:

7507803, Mar 24, 2009

Filed:

Oct 3, 2003

Appl. No.:

10/677754

Inventors:

Alessandro Sette - La Jolla CA, US
Robert Chesnut - Cardiff-by-the-Sea CA, US
Mark J. Newman - Carlsbad CA, US
Brian D. Livingston - San Diego CA, US
Lilia Maria Babe - Emerald Hills CA, US
Yiyou Chen - San Jose CA, US
Lawrence M. Deyoung - Montara CA, US
Manley T. F. Huang - Palo Alto CA, US
Scott D. Power - San Bruno CA, US

Assignee:

Genimmune N.V. - Zwijnaarde

International Classification:

C07H 21/04

US Classification:

536 231

Abstract:

The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity.

US Patent:

7888472, Feb 15, 2011

Filed:

Mar 20, 2009

Appl. No.:

12/408472

Inventors:

Alessandro Sette - La Jolla CA, US
Robert Chesnut - Cardiff-by-the-Sea CA, US
Mark J. Newman - Carlsbad CA, US
Brian D. Livingston - San Diego CA, US
Lilia Maria Babe - Emerald Hills CA, US
Yiyou Chen - San Jose CA, US
Lawrence M. Deyoung - Montara CA, US
Manley T. F. Huang - Palo Alto CA, US
Scott D. Power - San Bruno CA, US

Assignee:

Epimmune Inc. - San Diego CA
GENimmune N.V. - Zwijnaarde

International Classification:

C07K 14/00
A61K 39/00

US Classification:

530350, 4241841, 4242251

Abstract:

The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity.

US Patent:

20040248113, Dec 9, 2004

Filed:

Jun 8, 2004

Appl. No.:

10/474960

Inventors:

Alessandro Sette - La Jolla CA, US
Robert Chesnut - Cardiff-by-the-Sea CA, US
Brian Livingston - San Diego CA, US
Denise Baker - Poway CA, US
Mark Newman - Carlsbad CA, US
David Brown - San Diego CA, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/006000, 702/020000

Abstract:

The invention relates to the field of biology. In particular, the invention relates to a method and system for designing optimized multi-epitope vaccines having selected combinations of spacer nucleic acid at the junctions of the multi-epitope constructs encoding a plurality of CTL and/or HTL eoutioe oeotudes so as to minimize the number of junciontal epitopes and provide vaccines with increased immunogenicity.

US Patent:

20040248833, Dec 9, 2004

Filed:

Aug 2, 2004

Appl. No.:

10/485610

Inventors:

R Emanuele - San Diego CA, US
Konstantin Kousoulas - Baton Rouge LA, US
Hameedsulthan Allaudeen - Oakdale CT, US
Mark Newman - Carlsbad CA, US

International Classification:

A61K048/00
A61K009/14

US Classification:

514/044000, 424/486000

Abstract:

The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a therapeutic delivery composition effective for treating a disease state comprising an administerable admixture of an effective amount of a therapeutic compound capable of altering nucleic acid sequence function and an effective amount of a block copolymer having the following general formula: Wherein, the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is between about 5000 and about 7000 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes between about 10% to about 40% of the compound by weight; and bi s a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes between about 30 60% and about 90% of the compound by weight. The present invention also includes compositions and methods using biologically active reverse block copolymers. The reverse copolymers.

US Patent:

20060093617, May 4, 2006

Filed:

May 31, 2005

Appl. No.:

11/140487

Inventors:

Marie-Ange Buyse - Merelbeke, BE
Geert Maertens - Brugge, BE
Erik Depla - Destelbergen, BE
Ignace Lasters - Antwerpen, BE
Johan Desmet - Kortrijk, BE
Denise Baker - Poway CA, US
Robert Chesnut - Cardiff-by-the-Sea CA, US
Mark Newman - Carlsbad CA, US
Alessandro Sette - La Jolla CA, US
John Sidney - San Diego CA, US
Scott Southwood - Santee CA, US

Assignee:

Innogenetics, N.V. - Ghent
EPIMMUNE INC. - San Diego CA

International Classification:

A61K 39/29
C07K 14/18

US Classification:

424189100, 530350000

Abstract:

The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients.

US Patent:

20070014810, Jan 18, 2007

Filed:

Jan 3, 2005

Appl. No.:

11/027670

Inventors:

Denise Baker - Poway CA, US
Scott Power - San Bruno CA, US
Mark Newman - Carlsbad CA, US
Robert Chesnut - Cardiff-by-the Sea CA, US
Scott Southwood - Santee CA, US
Bianca Mothe - Oceanside CA, US
Manley Huang - Palo Alto CA, US
Lilia Babe - Emerald Hills CA, US
Lawrence DeYoung - Montara CA, US
Yiyou Chen - San Jose CA, US

International Classification:

C12Q 1/70
C07H 21/04
A61K 39/12
C12N 7/00
C07K 14/025

US Classification:

424186100, 435005000, 435235100, 530350000, 536023720

Abstract:

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

US Patent:

20070054262, Mar 8, 2007

Filed:

Mar 29, 2004

Appl. No.:

10/551209

Inventors:

Denise Baker - Poway CA, US
Brian Livingston - San Diego CA, US
Robert Chesnut - Cardiff-by-the-Sea CA, US
Alessandro Sette - La Jolla CA, US
Mark Newman - Carlsbad CA, US

International Classification:

C12Q 1/70
G01N 33/569
G01N 33/554
G01N 33/53

US Classification:

435005000, 435007220, 435007310, 435007320

Abstract:

The present invention is directed to methods for selecting a variant of a peptide epitope which induces a CTL response against another variant(s) of the peptide epitope, by determining whether the variant comprises only conserved residues, as defined herein, at non-anchor positions in comparison to the other variant(s). The present invention is also directed to variants identified by the methods above; peptides comprising such variants; nucleic acids encoding such variants and peptides; cells comprising such variants, and/or peptides, and/or nucleic acids; compositions comprising such variants, and/or peptides, and/or nucleic acids, and/or cells; as well as therapeutic and diagnostic methods for using such variants, peptides, nucleic acids, cells, and compositions.